Alnylam Pharmaceuticals Inc

詳細情報 Alnylam Pharmaceuticals Inc 企業名

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

企業情報

企業コードALNY

会社名Alnylam Pharmaceuticals Inc

上場日May 28, 2004

最高経営責任者「CEO」Dr. Yvonne L. Greenstreet, M.D.

従業員数2230

証券種類Ordinary Share

決算期末May 28

本社所在地675 W Kendall St

都市CAMBRIDGE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02142-1168

電話番号16175518200

ウェブサイトhttps://www.alnylam.com/

企業コードALNY

上場日May 28, 2004

最高経営責任者「CEO」Dr. Yvonne L. Greenstreet, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

56.63K

+14.74%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

50.18K

+4.96%

Mr. Tolga Tanguler

Chief Commercial Officer

25.99K

-7.21%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

56.63K

+14.74%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

50.18K

+4.96%

Mr. Tolga Tanguler

Chief Commercial Officer

25.99K

-7.21%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

事業別USD

会社名

収益

比率

AMVUTTRA

309.99M

52.17%

GIVLAARI

66.97M

11.27%

Other

57.56M

9.69%

Regeneron Pharmaceuticals

51.04M

8.59%

ONPATTRO

49.49M

8.33%

他の

59.15M

9.95%

地域別USD

会社名

収益

比率

United States

271.44M

45.68%

Europe

146.16M

24.60%

Net revenues from collaborations

99.19M

16.69%

Rest of World

50.94M

8.57%

Royalty revenue

26.47M

4.45%

事業別

地域別

事業別USD

会社名

収益

比率

AMVUTTRA

309.99M

52.17%

GIVLAARI

66.97M

11.27%

Other

57.56M

9.69%

Regeneron Pharmaceuticals

51.04M

8.59%

ONPATTRO

49.49M

8.33%

他の

59.15M

9.95%

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

Capital World Investors

12.82%

Fidelity Management & Research Company LLC

11.48%

The Vanguard Group, Inc.

10.10%

Capital Research Global Investors

5.49%

BlackRock Institutional Trust Company, N.A.

4.98%

他の

55.13%

株主統計

比率

Capital World Investors

12.82%

Fidelity Management & Research Company LLC

11.48%

The Vanguard Group, Inc.

10.10%

Capital Research Global Investors

5.49%

BlackRock Institutional Trust Company, N.A.

4.98%

他の

55.13%

種類

株主統計

比率

Investment Advisor

67.79%

Investment Advisor/Hedge Fund

21.50%

Hedge Fund

3.75%

Corporation

3.39%

Research Firm

1.74%

Sovereign Wealth Fund

1.65%

Pension Fund

1.31%

Bank and Trust

1.08%

Individual Investor

0.40%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

1300

131.78M

100.54%

-3.28M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

2023Q1

1116

123.13M

99.37%

-5.56M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Capital World Investors

16.75M

12.85%

+149.10K

+0.90%

Mar 31, 2025

Fidelity Management & Research Company LLC

14.62M

11.22%

+1.68M

+13.00%

Mar 31, 2025

The Vanguard Group, Inc.

13.00M

9.97%

+322.72K

+2.55%

Mar 31, 2025

Capital Research Global Investors

7.15M

5.49%

+186.22K

+2.67%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.73M

5.16%

-22.21K

-0.33%

Mar 31, 2025

Regeneron Pharmaceuticals Inc

4.44M

3.41%

--

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

4.42M

3.39%

+33.70K

+0.77%

Mar 31, 2025

Dodge & Cox

3.35M

2.57%

-188.50K

-5.32%

Mar 31, 2025

State Street Global Advisors (US)

3.37M

2.58%

-56.29K

-1.64%

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.41M

2.61%

+178.26K

+5.52%

Mar 31, 2025

詳細を見る

446.400USD

Alnylam Pharmaceuticals Inc

446.400

概要

企業名

金融

分析